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Abstract 31 
 32 
Triple negative breast cancer (TNBC) accounts for a disproportionately high number of deaths 33 
due to lack of targeted therapies and increased likelihood of distant recurrence. Estrogen receptor 34 
beta (ERβ), a well characterized tumor suppressor, is expressed in 30% of TNBCs and its 35 
expression is associated with improved patient outcomes. We demonstrate that therapeutic 36 
activation of ERβ elicits potent anti-cancer effects in TNBC through the induction of a family of 37 
secreted proteins known as the cystatins, which function to inhibit canonical TGFβ signaling and 38 
suppress metastatic phenotypes both in vitro and in vivo. These data reveal the involvement of 39 
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cystatins in suppressing breast cancer progression and highlight the value of ERβ targeted 40 
therapies for the treatment of TNBC patients.  41 
Significance Statement 42 
Triple negative breast cancer (TNBC) is the most aggressive form of breast cancer and patients 43 
exhibit high rates of recurrence and mortality in part due to lack of treatment options beyond 44 
standard of care chemotherapy regimens. In the subset of TNBCs that express estrogen receptor 45 
beta (ERβ), ligand-mediated activation of ERβ elicits potent anti-cancer effects. We report here 46 
the elucidation of the ERβ cistrome and transcriptome in TNBC and identify a novel mechanism 47 
whereby ERβ induces cystatin gene expression resulting in inhibition of canonical TGFβ 48 
signaling and blockade of metastatic phenotypes. These findings suggest that ERβ-targeted 49 
therapies represent a new treatment option for the subset of women with ERβ expressing TNBC. 50 
/body 51 
Introduction 52 
In the United States, breast cancer is the second most common cancer among women and is 53 
responsible for over 40,000 deaths each year (1). As with all cancers, breast cancer is a 54 
heterogeneous disease composed of genomically distinct subtypes defined clinically by the 55 
presence of three key biomarkers: estrogen receptor alpha (ERα), the progesterone receptor (PR) 56 
and human epidermal growth factor receptor 2 (HER2) (2, 3). Triple negative breast cancer 57 
(TNBC) accounts for 10-20% of all breast cancers and is defined by the absence of these three 58 
biomarkers (4). TNBC typically presents in younger women, is more prevalent in individuals of 59 
African-American and Hispanic ancestry, and is clinically unique due to its aggressive and 60 
metastatic nature (2, 4-7). The standard of care for early stage TNBC patients includes 61 
chemotherapy, most commonly delivered prior to surgery. For patients with residual disease after 62 
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chemotherapy, upwards of 50% will develop recurrent disease (8) and nearly all patients who 63 
develop metastases succumb to their disease. For these reasons, identifying novel therapeutic 64 
strategies for these patients is of critical importance. 65 
 66 
Estrogen receptor beta (ERβ) is highly expressed in normal breast tissue; however, during the 67 
process of breast carcinogenesis, ERβ levels typically decrease (9-15). In cohorts of women with 68 
breast cancer, tumoral ERβ expression is associated with smaller tumor size, lymph-node 69 
negativity and lower histological grade (16, 17), supporting a tumor-suppressive role for this 70 
hormone receptor. ERβ has also been shown to decrease proliferation and to inhibit epithelial to 71 
mesenchymal transition (EMT) in TNBC cells (18-22). 72 
 73 
Using an antibody validated in a number of laboratories (23-26), we and others have identified 74 
that 30% of TNBCs express ERβ (21, 27, 28). ERβ expression in TNBC is associated with 75 
prolonged disease free survival and overall survival relative to patients with ERβ negative 76 
disease (27). These findings indicate that therapeutically targeting ERβ is a relevant strategy that 77 
should be further explored for TNBC patients. However, the mechanisms by which ERβ elicits 78 
tumor-suppressive effects in TNBC is not well understood. Such information is critical for 79 
monitoring response to therapy and for identifying sub-sets of patients that are most likely to 80 
benefit from ERβ targeted therapies.  81 
Results 82 
Identification of the ERβ cistrome in triple negative breast cancer cells 83 
Given our previous findings that approximately 30% of all triple negative breast cancers 84 
(TNBCs) express ERβ and that estrogen (E2) treatment of ERβ expressing TNBC cell lines 85 
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substantially inhibits cell growth (21), we first sought to assess the distribution of ERβ 86 
expression amongst the known molecular subtypes of TNBC: basal-like 1 and 2, mesenchymal 87 
and luminal androgen receptor (29). Using a cohort of TNBC patients extensively characterized 88 
at the DNA and RNA level (30), our data suggest that ERβ is expressed across all TNBC 89 
subtypes (SI Appendix, Table S1). 90 
 91 
We then sought to elucidate the mechanisms by which ERβ elicits its tumor-suppressive effects 92 
in TNBC cells. As a first step, we utilized ChIP-Seq to delineated the ERβ cistrome in MDA-93 
MB-231 cells that stably express ERβ following three hours of treatment with ethanol vehicle, 1 94 
nM E2, or 10 nM LY500307, an ERβ-selective agonist. Results of these studies identified 2,911 95 
ligand-independent ERβ binding sites in MDA-MB-231-ERβ cells (Figure 1A and B). A total of 96 
26,896 and 10,059 sites were identified following E2 and LY500307 treatment, respectively 97 
(Figure 1A and B). ERβ binding sites were distributed throughout the genome with the majority 98 
of sites localizing within introns followed by intergenic regions and transcriptional start sites 99 
(Figure 1C). Very few ERβ binding sites were localized within exons (Figure 1C). Ligand-100 
independent ERβ-bound chromatin regions showed significant enrichment of N-Myc and ER 101 
motifs, while the top two motifs enriched within both E2- and LY500307-induced ERβ binding 102 
sites were ER and AP1 response elements (Figure 1D). Comparison of all ERβ bound chromatin 103 
regions in vehicle, E2 and LY500307 treated cells demonstrated that nearly all of the ligand-104 
independent binding sites were also identified in ligand treated cells (Figure 1E). As expected, 105 
nearly all of the LY500307-induced ERβ binding sites were conserved within the sites identified 106 
following E2 treatment (Figure 1E). However, 5,762 ERβ bound regions were only present 107 
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following E2 treatment (Figure 1E). Similar patterns were observed when comparing ERβ bound 108 
regions that were located specifically within gene promoters and enhancers (Figures 1F & G).  109 
 110 
ERβ mediated gene expression profiles in TNBC cells 111 
In parallel with the ChIP-Seq experiments, we sought to characterize changes in the gene 112 
expression profiles of MDA-MB-231-ERβ cells following E2 treatment. Microarray analyses 113 
were performed using Illumina HT-12 BeadChips and the complete list of genes that met a p-114 
value ≤ 0.05 and an absolute fold change of 1.5 cut off between vehicle and E2 treated cells is 115 
provided in SI Appendix (Table S2). In total, 976 genes were differentially expressed in MDA-116 
MB-231-ERβ cells following estrogen treatment, with 578 genes being up-regulated and 398 117 
genes down-regulated (Figure 2A). Heat map analysis of the top 20 most induced and repressed 118 
genes following E2 treatment are depicted in Figure 2B. Multiple interleukins and other 119 
inflammation-related factors were enriched in the group of genes shown to be the most inhibited 120 
by E2 treatment while four members of the cystatin superfamily of cysteine proteases were 121 
among the top 20 most estrogen-induced genes (Figure 2B). Confirmation of the microarray 122 
dataset was performed using genes chosen at random (SI Appendix, Figure S1). A Venn diagram 123 
was constructed to reveal the overlap between the ChIP-Seq and microarray results (Figure 2D). 124 
Once replicate genes (i.e. genes containing multiple ERβ binding sites) were removed from the 125 
ChIP-Seq data set, a total of 11,401 genes were assigned as being associated with at least one 126 
ERβ binding site. Of the 976 genes shown to be regulated by estrogen treatment, 585 were 127 
shown to have a nearby ERβ binding site (Figure 2D). Gene set enrichment analysis (GSEA) was 128 
performed using a pre-ranked gene list comprising the 976 genes identified in the microarray 129 
analysis and revealed significant associations with phenotypes pertaining to breast cancer grade 130 
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and cancer metastasis (Figure 2C). Specifically, genes induced by E2 in MDA-MB-231-ERβ 131 
cells were also shown to exhibit increased expression in non-basal like breast cancer, low-grade 132 
breast cancer and non-metastatic cancers (Figure 2C). All four of the cystatins shown to be 133 
induced by estrogen in ERβ-expressing cells were found at the leading edge of each of the gene 134 
sets identified by GSEA. A dendrogram depicting the relationship between cystatins 1, 2, 4, and 135 
5 within the cysteine protease family is shown in Figure 2E as well as their expression levels in 136 
vehicle and estrogen treated MDA-MB-231-ERβ cells as determined by microarray analysis 137 
(Figure 2F). Regulation of cystatin gene expression by E2 was confirmed by RT-PCR in MDA-138 
MB-231-ERβ cells, as well as in a second ERβ-expressing TNBC cell line (Hs578T), and 139 
compared to the effects elicited by the ERβ-selective agonist LY500307 following 5 days of 140 
treatment (Figure 2G and H). In both models, all 4 cystatins were significantly induced by 141 
estrogen and LY500307 and there were no appreciable differences between the two ligands. 142 
However, the fold-increase for all 4 cystatin genes was approximately 10-fold less in the 143 
Hs578T-ERβ cells (Figure 2G and H). To examine the basis for this difference, we first assessed 144 
the basal expression levels of the 4 cystatins between these two cell lines in the absence and 145 
presence of doxycycline (dox) treatment. As shown in SI Appendix (Figure S2A), the basal 146 
expression levels of the cystatins were extremely low in the absence of dox in both cell lines. 147 
Following dox treatment, the expression levels increased approximately 2-fold in MDA-MB-148 
231-ERβ cells and 10-50-fold in Hs578T-ERβ cells. Interestingly, ERβ mRNA levels follow dox 149 
treatment were actually 10-fold lower in Hs578T-ERβ cells (SI Appendix, Figure S2B) 150 
suggesting that the apparent differences in cystatin induction by ERβ in these two models is 151 
explained by the more robust ligand-independent effects observed in the Hs578T-ERβ cell line.   152 
 153 
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Cystatins are highly induced by ERβ and correlate with relapse-free survival in TNBC 154 
Given the above findings, we next performed a time-course analysis of cystatin gene expression 155 
following E2 treatment of MDA-MB-231-ERβ cells. Cystatins 1, 2, 4 and 5 were shown to be 156 
significantly induced by E2 within 2-8 hours of exposure (Figure 3A), and continued to increase 157 
during extended treatment times of 1-5 days (Figure 3B). To confirm these findings at the protein 158 
level, immunohistochemistry for the most highly-induced cystatin, cystatin 5, was performed in 159 
MDA-MB-231-ERβ cell line pellets. Cystatin 5 staining was absent in vehicle treated cells, 160 
slightly positive following dox-induced ERβ expression and highly positive in the setting of E2 161 
treatment (Figure 3C). These ligand-independent effects of ERβ on cystatin gene expression 162 
were confirmed at the mRNA level, where dox treatment of MDA-MB-231-ERβ cells was 163 
shown to significantly induce the expression of cystatins 1, 2, 4 and 5 relative to no dox treated 164 
cells even in the absence of a ligand (Figure 3D). In addition, the E2-mediated induction of 165 
cystatin 1, 2, 4, and 5 expression was completely abolished by the pure anti-estrogen, fulvestrant 166 
(ICI 182,780) (Figure 3E). To determine if the induction of cystatins by E2 was unique to ERβ, 167 
we also analyzed their expression levels in ERα+ MCF7 and T47D breast cancer cells after 24 168 
hours of treatment (Figure 3F). Cystatins 1, 4 and 5 were completely undetectable by RT-PCR in 169 
both MCF7 and T47D cells while cystatin 2 demonstrated basal expression in T47D cells that 170 
was repressed with estrogen treatment (Figure 3F). Further, estrogen treatment of ERα-171 
expressing MDA-MB-231 and Hs578T cells had no effect on the expression levels of cystatins 1, 172 
2, 4 and 5 with the exception of a slight induction of cystatin 1 in the MDA-MB-231 model (SI 173 
Appendix, Figure S3). To determine the potential relevance of these cystatins in breast cancer, 174 
we examined their association with patient outcomes using the online Kaplan Meier plotter 175 
program in the breast cancer dataset (31). Using the multigene classifier for cystatins 1, 2, 4 and 176 
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5, high cystatin expression was significantly associated with improved relapse-free survival 177 
(RFS) in TNBC patients but not in ER
+
/PR
+
 patients (Figure 3G). Together these data indicate 178 
that cystatins are highly induced by E2 in an ERβ-specific manner and are positively correlated 179 
with improved RFS in TNBC patients.   180 
 181 
Direct regulation of cystatin gene expression by ERβ 182 
To identify the mechanisms by which ERβ induces cystatin gene expression, we interrogated the 183 
ChIP-Seq data and identified ERβ-bound regions within the promoter of all four cystatins as well 184 
as the first intron of cystatins 1, 4 and 5 (Figure 4A). An ERβ-bound region far upstream of the 185 
transcriptional start site of cystatin 2 was also indicated (Figure 4A). ERβ was shown to be 186 
associated with the promoter of cystatin 4 and 5 both in the absence and presence of a ligand, 187 
while its association with the cystatin 1 and 2 promoter was ligand-dependent (Figure 4A). ERβ 188 
association with intron 1 was also ligand-dependent for cystatins 4 and 5 but ligand independent 189 
for cystatin 1 (Figure 4A). These binding sites were centered over estrogen response elements 190 
(EREs) and a schematic showing the homology of a consensus ERE with the identified cystatin 191 
specific EREs are shown in Figure 4B. ChIP-PCR using the ERβ specific MC10 antibody was 192 
used to confirm ERβ association with selected EREs (Figure 4C). Given the nearly identical 193 
sequence homology between cystatins 1, 2 and 4, and their divergence from cystatin 5, we 194 
focused on cystatins 4 and 5 in future analyses. E2 treatment was shown to enhance ERβ 195 
association on the cystatin 4 and 5 promoters with only a trend towards increased binding in the 196 
setting of E2 on the ERE within intron 1 of cystatin 5 (Figure 4C).   197 
 198 
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To assess the activity of the identified EREs, a 500 base pair region centered on the ERβ binding 199 
site in the cystatin 4 and 5 promoter and intron were cloned into a luciferase reporter construct. 200 
With the exception of the cystatin 4 promoter construct, E2 treatment was shown to induce 201 
luciferase activity following transfection into MDA-MB-231-ERβ cells, effects that were 202 
completely abolished by ICI (Figure 4D). Site-directed mutagenesis was used to eradicate the 203 
EREs identified in the cystatin 5 promoter and cystatin 4 and 5 introns. Mutation of these EREs 204 
was also shown to abolish estrogen-induced luciferase activity (Figure 4E) confirming the 205 
involvement of these sites in ERβ-mediated induction of cystatin gene expression.    206 
 207 
Biological effects of cystatins in TNBC cells 208 
Given these findings, we sought to better understand the potential biological effects of cystatins 209 
in TNBC cells. Ingenuity pathway analysis of our microarray data revealed significant changes 210 
in multiple canonical signaling pathways (SI Appendix, Table S3). The top pathway identified 211 
pertained to fibrosis and consisted of numerous genes known to be involved in TGFβ signaling. 212 
Furthermore, upstream regulator analysis identified core components of the TGFβ signaling 213 
pathway including Smad4 and TGFβ1 (SI Appendix, Table S4) suggesting that ligand-mediated 214 
activation of ERβ impacts the TGFβ signaling pathway in TNBC cells. Based on these findings, 215 
we constructed a heat map consisting of known TGFβ pathway genes from the microarray data 216 
(Figure 5A). We also examined the effects of 24 hours or 5 days of estrogen treatment on the 217 
TGFβ signaling pathway using a TGFβ pathway PCR array. These data confirmed that estrogen 218 
treatment of ERβ expressing MDA-MB-231 cells significantly alters the expression of multiple 219 
genes within the canonical TGFβ pathway (Figure 5B). In order to determine if estrogen-220 
mediated induction of cystatins impacted TGFβ signaling, we next analyzed the phosphorylation 221 
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levels of Smad2 and Smad3 following TGFβ stimulation in the presence and absence of a 222 
combination of recombinant cystatins 1, 2, 4 and 5. Pre-treatment of non-ERβ expressing 223 
parental MDA-MB-231 cells with recombinant cystatins resulted in blockade of Smad2 and 224 
Smad3 phosphorylation by TGFβ (Figure 5C). In parallel, recombinant cystatins were also 225 
shown to suppress the ability of TGFβ to induce a Smad-binding element (SBE) luciferase 226 
reporter construct (Figure 5D), demonstrating that cystatins inhibit TGFβ signaling. 227 
Interestingly, TGFβR2 and cystatin 5 were shown to co-localize in MDA-MB-231-ERβ cells 228 
following E2 treatment (Figure 5E). An interaction between cystatin 5 and TGFβR2 in the 229 
setting of estrogen treatment was confirmed using a duolink proximity assay as indicated by the 230 
punctate red staining (Figure 5F). Taken together, these data indicate that cystatins interact with 231 
TGFβR2 to inhibit canonical TGFβ signaling in TNBC cells. 232 
 233 
ERβ-mediated induction of cystatins inhibit TNBC cell invasion and migration 234 
In light of the invasive and migratory properties of TNBC, and the known roles of TGFβ 235 
signaling in driving breast cancer cell invasion and migration (32-35), we analyzed the impact of 236 
ERβ on these cellular properties. Invasion and migration of MDA-MB-231-ERβ and Hs578T-237 
ERβ cells were analyzed using transwell assays following treatment with no dox vehicle control, 238 
dox vehicle, dox + 1 nM estrogen, or dox + 10 nM LY500307. Dox-induced expression of ERβ 239 
resulted in suppression of both MDA-MB-231-ERβ and Hs578T-ERβ cell invasion and 240 
migration, even in the absence of a ligand (Figure 6A-H). These inhibitory effects were 241 
significantly magnified following treatment with either E2 or LY500307 (Figure 6A-H).  242 
 243 
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Since cystatins are secreted proteins that are highly induced by ERβ and are capable of inhibiting 244 
canonical TGFβ signaling, we sought to determine their ability to suppress TNBC cell invasion. 245 
siRNA-mediated knockdown was optimized for each individual cystatin and all siRNAs were 246 
shown to block E2-mediated induction of the cystatins in MDA-MB-231-ERβ cells (Figure 6I). 247 
Combinatorial knockdown of all 4 cystatins was shown to block the ability of E2 to suppress cell 248 
invasion (Figure 6J). Treatment of parental MDA-MB-231 cells with recombinant cystatins was 249 
also shown to completely suppress TGFβ-mediated invasion, effects that were significantly 250 
greater than that of a TGFβ-specific inhibitor, SB431542 (Figure 7A and B). Combined, these 251 
data show that ligand-mediated activation of ERβ substantially inhibits the invasive and 252 
migratory properties of TNBC cells in part through the actions of cystatins and suppression of 253 
TGFβ signaling. 254 
 255 
ERβ activation prevents lung metastasis of MDA-MB-231 cells in vivo 256 
A common site of TNBC metastasis is the lung; therefore, we sought to determine the effect of 257 
ERβ activation on the ability of TNBC cells to establish lung colonization in vivo as a model of 258 
metastasis. MDA-MB-231-ERβ-Luc cells were injected into the tail vein of ovariectomized 259 
athymic nude mice and randomized to one of three treatment arms: normal chow/placebo pellet, 260 
dox chow/placebo pellet or dox chow/estrogen pellet with eight mice in each group. Mice were 261 
monitored for the development of lung metastases via IVIS2000 xenogen imaging. 262 
Representative images from animals in each treatment arm are shown prior to sacrifice (Error! 263 
Reference source not found. 8A). Following sacrifice, metastatic lesions were quantitated in the 264 
lungs under a dissecting scope, and representative images of tumor nodules in the no dox placebo 265 
and dox placebo groups (10x magnification) are shown (Figure 8B). No macroscopic lung 266 
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nodules were observed in any of the animals in the dox estrogen group, effects that were 267 
confirmed following histological analysis for microscopic lesions (Figure 8C). Percent tumor 268 
incidence (Figure 8D), number of lung nodules (Figure 8E) and average tumor volume (Figure 269 
8F) were also evaluated for each treatment group. These studies confirm the in vitro findings 270 
presented above and demonstrate that ligand-mediated activation of ERβ is capable of preventing 271 
the development of metastatic lesions in vivo. 272 
Discussion 273 
In this study we sought to characterize the biological effects of targeting ERβ in TNBC cells and 274 
to elucidate the mechanisms of action through which it functions in this form of the disease. For 275 
the first time, we have characterized the ERβ cistrome in TNBC cells and have determined the 276 
effects of E2 on the global gene expression profiles of MDA-MB-231-ERβ cells. Microarray 277 
analysis revealed estrogen-mediated induction of a family of genes known as cystatins and ChIP-278 
Seq analysis identified ERβ binding sites within the promoter and intronic regions of these 279 
genes. These ERβ binding sites were confirmed to be occupied by ERβ and were shown to be 280 
transcriptionally active following exposure to ERβ agonists. Ligand-mediated activation of ERβ 281 
with estrogen or LY500307 resulted in decreased invasion and migration of TNBC cells in vitro 282 
and prevented the formation of lung metastasis in vivo. Taken together, we propose a novel 283 
mechanism through which ERβ elicits tumor-suppressive effects, particularly with regard to 284 
suppression of metastatic phenotypes, which is characterized by the induction of cystatins and 285 
the subsequent inhibition of canonical TGFβ signaling. 286 
 287 
ChIP-Seq analysis identified nearly 30,000 ERβ binding sites across the genome of which the 288 
large majority were ligand-dependent. Estrogen treatment of MDA-MB-231-ERβ cells resulted 289 
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in significantly more enrichment of ERβ on DNA compared to the ERβ specific agonist 290 
LY500307. This discrepancy could be a result of differential receptor conformation when these 291 
two ligands are bound and/or alterations in co-factor recruitment. However, it is worth noting 292 
that nearly all of the LY500307-induced ERβ binding sites were conserved among the E2-293 
induced binding sites suggesting that these differences could also be explained by a difference in 294 
the IC50 for these two ligands. As is the case with ERα (36, 37), the large majority of ERβ 295 
binding sites were located in introns or intergenic regions of chromatin indicating that ERβ 296 
primarily occupies enhancer regions across the genome.    297 
 298 
In parallel to the ChIP-Seq studies, microarray analysis was performed to identify genes 299 
differentially regulated by ERβ following estrogen treatment. Through this analysis, we 300 
identified over 900 genes that were significantly induced or repressed and demonstrated that 301 
genes whose expression was up-regulated by ERβ were associated with less aggressive breast 302 
cancer phenotypes and decreased metastatic potential. Of the most highly induced transcripts, 303 
four were members of a superfamily of genes known as the cystatins, specifically cystatins 1, 2, 304 
4 and 5. These four genes were shown to be specifically induced by E2 in an ERβ-specific 305 
manner as their expression levels were either completely absent or repressed by E2 in ERα 306 
positive breast cancer cells and since they were not induced by estrogen in ERα-expressing 307 
MDA-MB-231 or Hs578T cells. Cystatins are small secreted proteins that have previously been 308 
shown to function as cysteine protease inhibitors (38-40). While extensive research has been 309 
performed on a closely related family member, cystatin 3 (41), relatively little is known about 310 
cystatins 1, 2, 4 and 5.  Further, nothing is known about the expression levels or function of these 311 
four cystatins in breast cancer.  312 
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 313 
ERβ has previously been shown to be a prognostic factor in TNBC, as high expression of this 314 
receptor is associated with improved overall survival (OS), disease-free survival (DFS), and 315 
distant metastasis-free survival (DMFS) (27). Given our findings that ligand mediated activation 316 
of ERβ results in substantial increases in cystatin gene expression in TNBC, we analyzed the 317 
association of cystatin 1, 2, 4 and 5 expression levels with relapse-free survival of TNBC 318 
patients. Intriguingly, high expression of all four cystatins correlated with improved relapse-free 319 
survival, but only in TNBC patients and not in breast cancer patients expressing ERα and PR. 320 
These findings are in agreement with the results of the present study implicating important 321 
tumor-suppressive effects of cystatins in TNBC. Furthermore, these data suggest that monitoring 322 
cystatin expression levels may have prognostic and/or predictive value in this form of the 323 
disease.     324 
 325 
Utilizing our ChIP-Seq dataset, we were able to identify ERβ binding sites within the promoter 326 
and intronic regions of each of the four cystatin genes shown to be induced by E2 treatment in 327 
TNBC cells. These binding sites encoded functional EREs that were activated by ERβ in a 328 
ligand-dependent manner. ERβ was also shown to occupy some of these binding sites in a ligand 329 
independent fashion. This likely explains our findings that expression of ERβ alone, even in the 330 
absence of a ligand, is capable of causing a slight induction of cystatin gene expression. These 331 
findings demonstrate that ERβ directly associates with these regulatory elements to enhance 332 
cystatin gene expression in TNBC cells.  333 
 334 
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Although the cystatins were among the most highly regulated genes following E2 treatment of 335 
TNBC cells, it was not immediately obvious as to what effect, if any, they may have on TNBC 336 
cell biology. We therefore returned to our gene expression dataset and identified alterations in 337 
the TGFβ signaling pathway through the use of Ingenuity Pathway Analysis. Furthermore, these 338 
analyses predicted that our gene expression signature correlated with decreased TGFβ ligand 339 
activity. TGFβ signaling is a known driver of metastasis, disease progression, and resistance to 340 
chemotherapy in TNBC (42, 43) and activation of TGFβ signaling is associated with worse 341 
outcomes for breast cancer patients (33, 44). Given that a previous study has linked the closely 342 
related family member, cystatin 3, with decreased TGFβ pathway activity (45) we speculated 343 
that increased expression of cystatins by ERβ may result in suppression of TGFβ signaling in 344 
TNBC cells. Indeed, we demonstrated that cystatins block canonical TGFβ signaling in breast 345 
cancer cells likely due to their ability to directly interact with the TGFβR2 resulting in inhibition 346 
of TGFβ ligand occupancy.   347 
 348 
Given that activation of the TGFβ pathway drives invasiveness in TNBC (42, 43), and in light of 349 
our findings that ERβ induces the expression of cystatins capable of inhibiting canonical TGFβ 350 
signaling, we sought to determine the effects of ERβ on TNBC cell invasion and migration. Our 351 
data demonstrate that the presence of ERβ, even in the absence of a ligand, suppresses both 352 
invasion and migration of TNBC cells, effects that are dramatically magnified by treatment with 353 
E2 or the ERβ selective agonist, LY500307. ERβ-mediated inhibition of invasion and migration 354 
is dependent on the biological activities of the cystatins since suppression of cystatin gene 355 
expression reverses these effects. Furthermore, we demonstrated that cystatins are capable of 356 
blocking TGFβ-induced cell invasion, effects that were even stronger than a TGFβ inhibitor. 357 
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These in vitro effects were confirmed in an in vivo metastatic mouse model, where ligand 358 
mediated activation of ERβ was shown to completely block lung colonization of TNBC cells.   359 
Conclusion  360 
In conclusion, our data elucidate the ERβ cistrome in TNBC and identify and characterize the 361 
functional roles of cystatins in this disease. The present report builds upon prior data that ERβ is 362 
expressed in approximately 30% of TNBC patients and that ligand mediated activation of ERβ 363 
suppresses TNBC cell proliferation (21) and tumor progression (18, 46). Our results lend further 364 
support to the notion that therapeutic targeting of ERβ may elicit clinical benefit for TNBC 365 
patients, and that this effect is dependent on ERβ to induce tumoral expression of cystatins. 366 
These results lay the foundation for future studies aimed at analyzing the anti-tumor activity of 367 
estrogen and ERβ selective agonists in ERβ positive TNBC patients.  368 
 369 
Materials and Methods 370 
Detailed information regarding the cell lines, chemical, reagents and procedures utilized in these 371 
studies are described in SI Appendix, SI Materials and Methods. 372 
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 499 
Figure Legends 500 
Figure 1. Identification of the ERβ cistrome in MDA-MB-231 TNBC cells.   501 
(A) Heat map of ERβ tag densities in MDA-MB-231-ERβ cells treated with vehicle, estrogen or 502 
LY500307 for 3 hours. (B) Total peaks called for each treatment. (C) Global distribution of 503 
binding sites among treatments. (D) Top 2 motifs identified, and their peak distributions, for 504 
each condition. Venn diagrams indicating overlap of all binding sites (E), promoter region-505 
specific binding sites (F) and enhancer regions (G) between treatment conditions. 506 
Figure 2. ERβ regulated gene expression signatures in TNBC cells.    507 
(A) Pie chart depicting the number of estrogen regulated genes in MDA-MB-231-ERβ cells 508 
following 5 days of treatment. (B) Heat map depicting expression levels of the top 20 most 509 
highly up- and down-regulated genes following estrogen treatment. (C) Gene Set Enrichment 510 
Analysis of the microarray data indicating associations of ERβ specific gene signatures with 511 
multiple cancer related phenotypes. (D) Venn diagram indicating overlap between genes 512 
identified as having nearby ERβ binding sites via ChIP-Seq and genes significantly regulated by 513 
estrogen treatment from the microarray data sets. (E) Dendogram indicating relationship of 514 
cystatins identified to be significantly up-regulated by ERβ in response to estrogen treatment. (F) 515 
RT-PCR confirmation of the microarray data for cystatins 1, 2, 4 and 5 in response to estrogen 516 
treatment of MDA-MB-231-ERβ cells. (G & H) Independent RT-PCR confirmation of cystatin 517 
induction following 1 nM E2 or 10 nM LY500307 treatment for 5 days in MDA-MB-231-ERβ 518 
and Hs578T-ERβ cells. Data are represented as average ± SEM. *denotes p-value <0.05 relative 519 
to vehicle treated control cells. 520 
Figure 3. ERβ specific regulation of cystatins in TNBC cells.   521 
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(A-B) RT-PCR analysis of cystatin 1, 2, 4 and 5 expression levels following estrogen treatment 522 
of MDA-MB-231-ERβ cells for indicated times. (C) Immunohistochemistry analysis of cystatin 523 
5 protein levels in MDA-MB-231-ERβ cell pellets treated as indicated for 5 days. (D) mRNA 524 
expression levels of cystatin 5 as detected by RT-PCR in MDA-MB-231-ERβ cells treated as 525 
indicated for 5 days, images taken at 40x magnification. (E) RT-PCR analysis demonstrating 526 
blockade of estrogen induced cystatin gene expression by the pure anti-estrogen, ICI. (F) RT-527 
PCR analysis of cystatin expression levels in ERα positive MCF7 and T47D cells following 528 
vehicle and estrogen treatment for 24 hours. (G) Kaplan-Meier plots depicting relapse-free 529 
survival (RFS) as a function of high and low cystatin 1, 2, 4 and 5 expression levels in ER/PR 530 
positive breast cancer vs TNBC. Data are represented as average ± SEM. * denotes p-value 531 
<0.05 relative to vehicle control treated cells. δ denotes p-value <0.05 between indicated 532 
treatments. 533 
Figure 4. Identification of ERβ regulatory elements responsible for mediating estrogen 534 
induced expression of cystatins 1, 2, 4 and 5.   535 
(A) Screen shots from the UCSC genome browser of ERβ signals from ChIP-Seq experiments on 536 
the promoters and first introns of indicated cystatin genes in MDA-MB-231-ERβ cells. (B)  537 
Comparison of a consensus ERE half-site to the EREs identified in the promoters and first 538 
introns of cystatins 1, 2, 4 and 5 via ERβ ChIP-Seq. (C) ChIP-PCR confirmation of ChIP-Seq 539 
data for indicated sites following pulldown with an ERβ-specific antibody (MC10) in MDA-MB-540 
231-ERβ cells. (D) Luciferase assays indicating basal and estrogen induced (24 hours) activity of 541 
indicated cystatin promoter and intronic regions encoding identified ERβ binding sites in MDA-542 
MB-231-ERβ cells.  (E) Luciferase assays depicting the estrogen mediated activity of indicated 543 
cystatin promoter and intronic elements following site-directed mutagenesis of the identified 544 
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EREs relative to wild type controls. Data are represented as average ± SEM. * denotes p-value 545 
<0.05 compared to vehicle treated control cells.  δ denotes p-value <0.05 compared to estrogen 546 
treated cells. 547 
Figure 5. Estrogen and cystatin mediated regulation of canonical TGFβ signaling in TNBC 548 
cells.   549 
(A) Heat map analysis of known TGFβ pathway genes shown to be differentially regulated by 550 
estrogen treatment in MDA-MB-231-ERβ expressing cells. (B) Heat maps generated from a 551 
TGFβ qPCR array indicating the effects of 24 hours or 5 days of estrogen treatment on indicated 552 
genes in MDA-MB-231-ERβ cells. (C) Western blot for phospho-Smad2, phospho-Smad3, total 553 
Smad2/3 and tubulin in MDA-MB-231 cell extracts. Cells were pre-treated with a combination 554 
of recombinant cystatins 1, 2, 4 and 5 for 6 hours followed by TGFβ (2ng/mL) or vehicle 555 
treatments for 30 minutes. (D) Luciferase assays indicating the activity of a Smad Binding 556 
Element reporter construct in parental MDA-MB-231 cells treated as indicated. (E) 557 
Immunofluorescent analysis of TGFβR2 (red) and cystatin 5 (green) proteins in MDA-MB-231-558 
ERβ cells treated as indicated for 24 hours. Representative images are shown at 20x 559 
magnification. (F) Proximity based duolink assay indicating interaction between cystatin 5 and 560 
TGFβR2 proteins (red dots) in MDA-MB-231-ERβ cells treated as indicated for 24 hours. 561 
Representative images are shown at 20x magnification. 562 
Figure 6. Cystatins mediate ERβ suppression of TNBC cell migration and invasion.    563 
Cell migration and invasion assays were performed with MDA-MB-231-ERβ and Hs578T-ERβ 564 
cell lines.  Representative images following indicated treatments are shown (A, C, E and G) and 565 
quantification of triplicate experiments ± SEM are indicated (B, D, F, H). (I) RT-PCR analysis 566 
indicating the efficacy of cystatin 1, 2, 4 and 5 siRNAs with regard to suppressing estrogen 567 
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induced cystatin gene expression in MDA-MB-231-ERβ cells. (J) Effects of siRNA mediated 568 
silencing of cystatin 1, 2, 4 and 5 expression on MDA-MB-231-ERβ cell invasion in the 569 
presence of indicated treatments. Data are represented as average ± SEM. * denotes p-value ≤ 570 
0.05 relative to -Dox/Veh controls. ** denotes p-value ≤ 0.01 relative to Dox/Veh cells 571 
following adjustment for multiple comparisons.   572 
Figure 7. Cystatins inhibit TGFβ-induced invasion in TNBC cells.    573 
(A) Representative images of parental MDA-MB-231 cell invasion assays following treatment 574 
with TGFβ ligand (2ng/mL), TGFβ + recombinant CST proteins (125 ng/ml of each recombinant 575 
cystatin), or TGFβ + SB431542 (10 µM/ml), a TGFβ specific inhibitor. (B) Quantification of 576 
triplicate invasion experiments ± SEM following indicated treatments. * denotes p-value ≤ 0.05 577 
relative to vehicle control treated cells. ** denotes p-value ≤ 0.01 relative to TGFβ treated cells 578 
following adjustment for multiple comparisons.   579 
Figure 8. Estrogen treatment inhibits lung colonization of ERβ-positive TNBC cells. 580 
MDA-MB-231-ERβ-Luciferase cells were injected into ovariectomized nude mice via the tail 581 
vein and randomized to indicated treatments. (A) IVIS2000 xenogen imaging indicating the 582 
presence of lung metastasis in mice randomized to the no dox placebo and dox placebo groups, 583 
but not in the dox estrogen group. (B) Gross images of lung nodules from representative animals 584 
in the indicated treatment groups (10x magnification). (C) Representative images depicting 585 
histological analysis of FFPE mouse lungs from animals in each treatment group following H&E 586 
staining and IHC analysis for ERβ at 40x magnification. Quantification of the incidence of lung 587 
nodules (D), the number of lung nodules (E) and the tumor volume of lung nodules (F) in mice 588 
randomized to the indicated treatment groups. * denotes p-value ≤ 0.01 relative to between 589 
indicated treatment groups following adjustment for multiple comparisons.  590 
